Pharmaceutical Formulations Containing Graphene and 5-Fluorouracil for Light-Emitting Diode-Based Photochemotherapy of Skin Cancer.
basal cell carcinoma
combined phototherapy
nanomaterials
nonmelanoma skin cancer (NMSC)
partially reduced nanographene oxide
pharmaceutical formulations
photothermal therapy
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
19 Jan 2024
19 Jan 2024
Historique:
medline:
19
1
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
aheadofprint
Résumé
Nonmelanoma skin cancer (NMSC) is the most common cancer worldwide, among which 80% is basal cell carcinoma (BCC). Current therapies' low efficacy, side effects, and high recurrence highlight the need for alternative treatments. In this work, a partially reduced nanographene oxide (p-rGOn) developed in our laboratory was used. It has been achieved through a controlled reduction of nanographene oxide via UV-C irradiation that yields small nanometric particles (below 200 nm) that preserve the original water stability while acquiring high light-to-heat conversion efficiency. The latter is explained by a loss of carbon-oxygen single bonds (C-O) and the re-establishment of sp
Identifiants
pubmed: 38240200
doi: 10.1021/acsami.3c13409
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM